Free Trial

Tim Lugo Analyst Performance

Analyst at William Blair

Tim Lugo is a stock analyst at William Blair in the medical sector, covering 9 publicly traded companies. Over the past year, Tim Lugo has issued 1 stock ratings, including and hold recommendations. While full access to Tim Lugo's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Tim Lugo's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
26 Last 10 Years
Buy Recommendations
88.46% 23 Buy Ratings
Companies Covered
9 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy88.5%23 ratings
Hold11.5%3 ratings
Sell0.0%0 ratings

Out of 26 total stock ratings issued by Tim Lugo at William Blair, the majority (88.5%) have been Buy recommendations, followed by 11.5% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
88.9% of companies on NASDAQ
8 companies
NYSE
11.1% of companies on NYSE
1 company

Tim Lugo, an analyst at William Blair, currently covers 9 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
9 companies
100.0%

Tim Lugo of William Blair specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
55.6%
MED - DRUGS
2 companies
22.2%
PHARMACEUTICAL PREPARATIONS
2 companies
22.2%

Tim Lugo's Ratings History at William Blair

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
12/17/2025Reiterated Rating$0.78Market Perform